Cencora, Inc. (NYSE:COR) Shares Sold by Aviva PLC

Aviva PLC lowered its position in shares of Cencora, Inc. (NYSE:COR) by 1.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 221,080 shares of the company’s stock after selling 4,223 shares during the quarter. Aviva PLC owned about 0.11% of Cencora worth $49,672,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of COR. Hickory Asset Management Inc. acquired a new stake in shares of Cencora in the fourth quarter worth $572,000. Sylvest Advisors LLC acquired a new stake in Cencora during the 4th quarter valued at $1,105,000. Insight Wealth Strategies LLC grew its holdings in Cencora by 124.6% during the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock valued at $4,549,000 after purchasing an additional 11,232 shares in the last quarter. Vontobel Holding Ltd. lifted its holdings in Cencora by 46.9% in the 4th quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company’s stock worth $1,403,000 after buying an additional 1,995 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. grew its stake in shares of Cencora by 71.1% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company’s stock valued at $1,583,000 after acquiring an additional 2,928 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total value of $3,928,916.78. Following the sale, the chairman now directly owns 317,913 shares in the company, valued at $85,680,732.63. This trade represents a 4.38 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 5,000 shares of the company’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the transaction, the executive vice president now owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,675 shares of company stock worth $8,034,778 in the last 90 days. 10.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. Wells Fargo & Company raised their price target on shares of Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a research report on Friday, March 14th. Evercore ISI upped their price target on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Cencora has a consensus rating of “Moderate Buy” and a consensus price target of $280.20.

Cencora Stock Down 3.5 %

Shares of NYSE:COR opened at $279.29 on Friday. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $296.65. The company’s fifty day moving average is $257.28 and its two-hundred day moving average is $242.70. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock has a market capitalization of $54.16 billion, a price-to-earnings ratio of 39.73, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were given a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.79%. Cencora’s dividend payout ratio is currently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.